Mikrobiologi.net

Gulsen Özkaya Sahin CV, page 1

Gulsen Özkaya Sahin CV

9. Deductible time Maternity leave between 2011-09-26 and 2012-05-01 (100%), 7 months

Nov 12, 2014: Research grant from Kungliga Fysiografiska Sällskapet i Lund, Sweden

Sep 13, 2013: Research grant from Crafoordska stiftelsen, Sweden

Nov 9, 2011: Research grant from Kungliga Fysiografiska Sällskapet i Lund, Sweden

2010: Doktorandmånader from Lund University (6 months), Sweden

Nov 10, 2010: Research grant from Kungliga Fysiografiska Sällskapet i Lund, Sweden Gulsen Özkaya Sahin CV, page 2

Feb 27-Mar 2, 2011: Travel grant for CROI, Boston, USA

Sep 28-Oct 1, 2010: Travel grant for AIDS Vaccine Conference, Atlanta, USA

Mar 21-26, 2010: Travel grant for Keystone Symposia (HIV Vaccines), Alberta, Canada

Mar 22-27, 2009: Travel grant for Keystone Symposia (HIV Vaccines), Colorado, USA

2007: ESCMID Grant for Research Fellowship, EU

2006: Scientific and Technical Research Council of the Turkish Republic Postdoctorate Scholarship Program, Turkey

2006: "Erasmus student" under the European Union Education and Youth programmes within the Framework of the Erasmus Programme, Turkey

2006: ESCMID Grant for Training in Foreign Laboratories, EU

1999: ECFMG (Educational Commission for Foreign Medical Graduates) Certificate, USA

2010, 2011 and 2014: Tutor at ‘HIV-AIDS week’, Biomedical Program, Lund University, Lund

2013-2015: Clinical tutor, internal medicine, AT-läkare, Närsjukvårdskliniken, Hässleholm

2008: Laboratory tutor: GHRC Training Workshop on Cryopreservation of Biologicla Material for Biological and Immunological Assays in HIV-Vaccine_Related Research, Sulzbach, Germany

Özkaya Sahin G. Anti-HIV antibodies and complement activity. EUROPRISE Antibodies Beyond Binding, May 31-June 1, 2011, Stockholm (Sweden).

Özkaya Sahin G. Effect of complement on neutralizing activity of HIV-1 and/or HIV-2 infected plasma. EUROPRISE Frontiers in HIV Vaccines and Microbicides, and Student Feature, May 2-5, 2011, Stockholm (Sweden)

Özkaya Sahin G. Treatment strategies for metabolic syndrome in HIV/AIDS cases. Clinical HIV/AIDS Symposium, Dec 11-12, 2010, Bodrum (Turkey)

Özkaya Sahin G. Comparison of the breadth and potency of neutralizing activity in HIV-1 and HIV-2 infection. EUROPRISE Rationale Design of HIV Vaccines and Microbicides Network Annual Conference, Nov 15-18, 2010, Lisbon (Portugal)

Özkaya Sahin G. Neutralizing activity induced in SIV and HIV.1/2 infections and the impact of complement system and its regulatory proteins on the effector functions of neutralizing antibodies. EUROPRISE Mucosal Immunity Workshop, April 29-30, 2009, Stockholm (Sweden)

Özkaya Sahin G. Neutralizing activity induced in SIV and HIV-1/2 infections and the impact of complement and its regulatory proteins on the effector functions of neutralizing antibodies. EUROPRISE Network of Excellence PhD Training Course, Nov 11-16, 2007, Stockholm (Sweden)

Özkaya Sahin G. Neutralizing activity induced in mice after immunization with apoptotic HIV-1/Murine Leukemia virus infected cells. 3rd Smögen Symposium Aug 8-9, 2007, Smögen (Sweden)

Özkaya Sahin G, Ozveren A, Shorbagi A, Akova M. Predictors of febrile response to antibacterial therapy in hematological malignancy patients with febrile neutropenia. 8th International Symposium on Febrile Neutropenia 26-28 January 2006, Athens, Greece (O-009) Gulsen Özkaya Sahin CV, page 3

Özkaya Şahin G. Recent developments in antiretroviral therapy. XXVIII. International Microbiology and Pathology Congress, 1-5 May 2005 İstanbul (Turkey).

Özkaya Şahin G, Ünal S, Hıncal F. A review of cutaneous anthrax in Turkey: experience of Hacettepe University medical center. The ASA Newsletter 2002;June28:issue number90:14-16.

Özkaya Sahin G, Mansson F, Fenyo EM, Norrgren H, Jansson M. Studies on neutralizing humoral immunity in genital mucosa of those infected with HIV-1 and/or HIV-2. Poster no: 327. Keystone Symposia HIV Vaccines, Keystone, Colorado, USA March 21-26, 2010.

Özkaya Sahin G, Khalil ES, Walther-Jallow L, Makitalo B, Spangberg M, Thorstensson R, Spetz AL, Fenyo EM. Induction of broadly neutralizing antibodies in Macaca fascicularis following SIV infection and short-term early antiretroviral therapy. Poster no: 409. Keystone Symposia HIV Vaccines, Keystone, Colorado, USA March 21-26, 2010.

Bowles EJ, Parker J, Uchtenhagen H, Özkaya Sahin G, Khalil ES, Achour A, fenyo EM, Spetz AL, Stewart-Jones G. Temporal analysis of SIVmac239 infection and evolution in 12 cynomolgus macaques. Poster no: 167. Keystone Symposia Viral Immunity, Keystone, Colorado, USA March 21-26, 2010.

Özkaya Sahin G, Shaik-Khalil E, Walther-Jallow L, Makitalo B, Spangberg M, Thorstensson R, Spetz AL, Fenyö EM. ‘SIVmac239 is a potent immunogen for the induction of neutralizing antibody response’. Poster no: 351. Keystone Symposia HIV Immunobiology, Keystone, Colorado, USA March 22-27, 2009.

Özkaya Sahin G, Walther-Jallow L, Makitalo B, Spanberg M, Thorstensson R, Spetz A-L, Fenyo EM. SIVmac239 is a potent immunogen for the induction of neutralizing antibody response. "25 years of HIV", May 19-21, 2008, Institut Pasteur, Paris, France (poster no: P2-36)

Sheik-Khalil E, Bray MA, Fraser AN, Heath A, Ozkaya Sahin G, Scarlatti G, Jansson M, Carpenter AE, Fenyö EM. High-throughput, automated, image-based assay for HIV neutralization by plaque reduction. BMC Infect Dis. 2014;14:472.

Ozkaya Sahin G, Mansson F, Palm A,Vincic E, da Silva Z, Medstrand P, Norrgren H, Fenyo EM, Jansson M. Frequent intratype neutralization by plasma immunoglobulin A identified in HIV-2 infection. AIDS Res Hum Retroviruses. 2013;29(3):470-8.

Ozkaya Sahin G, Holmgren B, Sheik-Khalil E, da Silva Z, Nielsen J, Nowroozalizadeh S, Mansson F, Norrgren H, Aaby P, Fenyo EM, Jansson M. Effect of complement on HIV-2 plasma antiviral activity is intratype-specific and potent. J Virol 2013;87(1):273-81.

Özkaya Sahin G, Holmgren B, da Silva Z, Nielsen J, Nowroozalizadeh S, Esbjörnsson J, Månsson F, Andersson S, Norrgren H, Aaby P, Jansson M, Fenyö EM. Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 from human immunodeficiency virus type 1. J Virol. 2012 Jan;86(2):961-71. Gulsen Özkaya Sahin CV, page 4

Purnak T, Beyazit Y, Sahin GO, Shorbagi A, Akova M. A novel fungal pathogen under the spotlight -Acremonium spp. associated fungaemia in an immunocompetent host. Mycoses 2011;54(1):78-80.

Özkaya Sahin G, Bowles EJ, Parker J, Uchtenhagen H, Khalil ES, Taylor S, Pybus O, Makitalo B, Jallow LW, Spangberg M, Thorstensson R, Achour A, Fenyö EM, Stewart-Jones GBE, Spetz AL. Generation of Neutralizing Antibodies and Divergence of SIVmac239 in Cynomolgus Macaques Following Short-term Early Antiretroviral Therapy. PLoS Pathogen 2010 Sep 2;6(9):e1001084.

Senocak E, Oguz KK, Ozgen B, Kurne A, Özkaya G, Unal S, Cila A. Imaging features of CNS involvement in AIDS. Diagn Interv Radiol 2010;16(3):193-200.

Kucukardali Y, Oncul O, Cavuslu S, Danaci M, Calangu S, Erdem H, Topcu AW, Adibelli Z, Akova M, Karaali EA, Ozel AM, Bolaman Z, Caka B, Cetin B, Coban E, Karabay O, Karakoc C, Karan MA, Korkmaz S, Şahin GO, Pahsa A, Sirmatel F, Solmazgul E, Ozmen N, Tokatli I, Uzun C, Yakupoglu G, Besirbellioglu BA, Gul HC; Fever of Unknown Origin Study Group. The spectrum of diseases causing fever of unknown origin in Turkey: a multicenter study. Int J Infect Dis 2008 Jan;12:71-9.

Altinbas A, Özkaya G, Buyukasik Y, Unal S. Rapid development of anemia in a HIV-positive patient with alpha-thalassemia after zidovudine therapy. Mikrobiyol Bull 2007;41:473-476 (Turkish).

Burnik C, Altintas ND, Özkaya G, Serter T, Selçuk ZT, Firat P, Arikan S, Cuenca-Estrella M, Topeli A. Acute respiratory distress syndrome due to Cryptococcus albidus pneumonia: case report and review of the literature. Med Mycol. 2007 Aug;45(5):469-73.

Özkaya G. The adventure of human immunodeficiency virus: from where to where? Mikrobiyol Bull 2006;40:435-443 (Turkish).

Özkaya G, Yildirim T, Aydin K, Erguven S, Unal S. A plasmodium alciparum malaria case originated from Mozambique: clues for the diagnosis and therapy. Mikrobiyol Bull 2006;40:407-411 (Turkish).

Ercis S, Ergin A, Özkaya Sahin G, Hascelik G, Uzun O. Validation of urinary antigen test for Streptococcus pneumoniae in patients with pneumococcal pneumonia. Jpn J Infect Dis 2006;59:388-390.

Özkaya G, Kurne A, Unal S, Oguz KK, Karabudak R, Saygi S. Aphasic status epilepticus with periodic lateralized epileptiform discharges in a bilingual patient as a presenting sign of "AIDS-toxoplasmosis complex". Epilepsy Behav 2006;9:193-196.

Sahin GO, Akova M. Treatment of invasive infections due to rare or emerging yeasts and moulds. Emerging moulds and yeasts and antifungal agents. Expert Opin Pharmacother 2006;7:1181-1190.

Leblebicioglu H, Yilmaz H, Tasova Y, Alp E, Saba R, Caylan R, Bakir M, Akbulut A, Arda B, Esen S, Study Group (Cagatay A, Ergin F, Bodur H, Sahin GO, Sencan I, Gurcan S, Doyuk E, Mete B, Oncul O). Characteristics and analysis of risk factors for mortality in infective endocarditis. Europ J Epidemiol 2006;21:25-31.

Kurne A, Özkaya G, Karlioguz K, Shorbagi A, Ustacelebi S, Karabudak R, Unal S. The colorful clinical spectrum of cerebral toxoplasmosis in five HIV positive cases: what comes out of Pandora's box? Mikrobiyol Bull 2006;40:85-92 (Turkish). Gulsen Özkaya Sahin CV, page 5

Tekeli A, Koyuncu E, Dolapci I, Guven GS, Sahin GO, Uzun O. Detection of Candida dubliniensis in oropharyngial samples of Turkish HIV-positive patients. Mycoses 2005;48:197-201.

Sahin GO, Akova M. Invasive Fungal Infections. Business Briefing: European Pharmacotherapy 2005:131-132.

Sahin GO, Akova M. Emerging and life-threatening fungal pathogens in the immunocompromised host. Business Briefing: European Oncology Review 2005:110-114.

Özkaya G, Shorbagi A, Ulger Z, Saglam A, Aybar M, Cetinkaya Sardan M, Uzun O. Invasive group A streptococcal infection with pancarditis caused by a new emm-type 12 allele of Streptococcus pyogenes. J Inf 2005:1-4.